Methotrexate for rheumatoid arthritis
93 results
1 - 93
Methotrexate for rheumatoid arthritis 
Methotrexate for treating rheumatoid arthritis- Biologics for people with rheumatoid arthritis naive to methotrexate
- Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis
- Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis
- Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
- Safety of non‐steroidal anti‐inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)
- Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta‐analysis
- Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis
- Rheumatoid arthritis
- Rituximab for rheumatoid arthritis
- Infliximab for the treatment of rheumatoid arthritis
- Juvenile idiopathic arthritis (juvenile rheumatoid arthritis)
- Adalimumab for treating rheumatoid arthritis
- Combination therapy in rheumatoid arthritis
Adding MTX to sulfasalazine better for RA (MASCOT)- Penicillamine for treating rheumatoid arthritis
- Golimumab for rheumatoid arthritis
- Golimumab for rheumatoid arthritis
- Rituximab for rheumatoid arthritis
- Adalimumab for treating rheumatoid arthritis
- Methotrexate for psoriatic arthritis
- Psoriatic arthritis
- Tocilizumab for rheumatoid arthritis
- Tocilizumab for rheumatoid arthritis
- 2010 classification criteria for rheumatoid arthritis
- Fish oil in rheumatoid arthritis
- Guidelines: Management of RA
- Iritis (inflammation of the iris)
- Infections in immunosuppressed and cancer patients
- Etanercept for the treatment of rheumatoid arthritis
- Certolizumab pegol for rheumatoid arthritis in adults
- Infliximab for rheumatoid arthritis
- Methotrexate for psoriatic arthritis
- Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
- RA options: MTX still first-line
- Cyclophosphamide for treating rheumatoid arthritis
- Auranofin versus placebo in rheumatoid arthritis
- Anakinra for rheumatoid arthritis
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta‐analysis
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics
- Updated ACR guideline on managing patients with rheumatoid arthritis
- Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)
- Leflunomide for the treatment of rheumatoid arthritis
- EULAR/ACR guideline on managing patients with polymyalgia rheumatica
- Etanercept for the treatment of rheumatoid arthritis
- Methotrexate for induction of remission in refractory Crohn's disease
- Methotrexate for ankylosing spondylitis
- Antidepressants for pain management in rheumatoid arthritis
- Chronic diseases and pregnancy
- Prolonged cough in adults
- Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)
- Leucopenia